Drug Profile
LY 326325
Latest Information Update: 22 Sep 2000
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antiepileptic drugs; Isoquinolines; Neuroprotectants; Tetrazoles
- Mechanism of Action AMPA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 22 Sep 2000 No-Development-Reported for Neurological disorders (Prevention) in USA (PO)
- 28 May 1998 New profile
- 27 May 1998 Preclinical development for Neurological disorders (Prevention) in USA (PO)